PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07444645
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Liver
- Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Y90 Microsphere Therapy — DEVICEGiven by injection
Study Details
This single-arm prospective study will compare CT-based tumor-to-normal ratio (TNR) measurements obtained using TriNav versus endhole microcatheters.
Key Dates
- Start date
- Aug 1, 2026
- Status verified
- Feb 2026
- Primary completion
- Jul 31, 2028
- Completion
- Jul 31, 2030
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DEVICE_FEASIBILITY
Arms
- Experimental: Single Arm Y90 RadioembolizationWill show an increase of TNR and TD as well as a reduction in NTLD by TriNav microcatheter.
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Peiman Habibollahi, MD(713) 792-4106
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas M. D. Anderson Cancer Center | Houston | Texas | 77030 | Peiman Habibollahi, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
Related Studies
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyRecruiting · UMC Utrecht · Pittsburgh, Pennsylvania
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver ImpairmentPHASE1 · Recruiting · Aadi Bioscience, Inc. · San Antonio, Texas
- Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical StudyPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas